<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537834</url>
  </required_header>
  <id_info>
    <org_study_id>DEBT02</org_study_id>
    <secondary_id>TOFOGL07279</secondary_id>
    <nct_id>NCT02537834</nct_id>
  </id_info>
  <brief_title>Tofogliflozin GLP-1 Analogue Combination Trial</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate 52-Week Long-Term Safety, Tolerability and Efficacy of Tofogliflozin With Glucagon-like Peptide-1(GLP-1) Analogue Treatment In Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and&#xD;
      efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Assessed by Adverse Event and Adverse Drug Reaction</measure>
    <time_frame>baseline and Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in HbA1c at 52 weeks</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting plasma glucose</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood pressure</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total cholesterol</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-C</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non HDL-C</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Free Fatty Acid</measure>
    <time_frame>baseline and week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Tofogliflozin ＋GLP-1 analogue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofogliflozin</intervention_name>
    <arm_group_label>Tofogliflozin ＋GLP-1 analogue</arm_group_label>
    <other_name>DEBERZA</other_name>
    <other_name>APLEWAY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 analogue</intervention_name>
    <arm_group_label>Tofogliflozin ＋GLP-1 analogue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject aged from 20 to 75 years old with type 2 diabetes mellitus(T2DM)&#xD;
&#xD;
          -  The subject with hemoglobin A1c ≧7.5% - &lt;10.5 %&#xD;
&#xD;
          -  The subject who has been receiving a stable dose and regimen of GLP-1 analogue over 8&#xD;
             weeks before Screening test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject with type 1 diabetes mellitus&#xD;
&#xD;
          -  The subject with Pregnancy or lactation&#xD;
&#xD;
          -  The subject with Fasting Plasma Glucose ≧ 270 mg/dl&#xD;
&#xD;
          -  The subject with history of metabolic acidosis, including diabetic ketoacidosis&#xD;
             ,within 1 year prior to screening&#xD;
&#xD;
          -  The subject with myocardial infarction, stroke, or heart failure requiring&#xD;
             hospitalization or drug or alcohol abuse within the previous 6 months&#xD;
&#xD;
          -  The subject with serum creatinine level greater than 2.0 mg/dL for men and 1.5 mg/dL&#xD;
             for women&#xD;
&#xD;
          -  The subject with aspartate aminotransferase(AST) or alanine aminotransferase(ALT) ≧&#xD;
             2.5 times the upper limit of the reference range at the central laboratory test&#xD;
             facility&#xD;
&#xD;
          -  The subject has received treatment with another investigational product or&#xD;
             non-approved drug 3 months before screening&#xD;
&#xD;
          -  The subject with history of Tofogliflozin therapy&#xD;
&#xD;
          -  The subject with estimated glomerular filtration rate of &lt;30 mL/min/1.73 m^2&#xD;
&#xD;
          -  The subject who frequently experiencing orthostatic hypotension&#xD;
&#xD;
          -  The subject systolic blood pressure of ≧ 180 or mmHg of diastolic blood pressure of ≧&#xD;
             100 mmHg&#xD;
&#xD;
          -  The subject required a change in the dosing regiment for the following drugs within 4&#xD;
             weeks before screening : Lipid-lowering drug , Antihypertensive drug, Thyroid hormone&#xD;
             drug , Uric acid lowering drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Atsuta-ku</city>
        <state>Aichi</state>
        <zip>456-0058</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Aichi</state>
        <zip>455-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kisarazu</city>
        <state>Chiba</state>
        <zip>292-0038</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annaka</city>
        <state>Gunma</state>
        <zip>379-0116</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naka</city>
        <state>Ibaraki</state>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0302</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasaoka</city>
        <state>Okayama</state>
        <zip>714-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimono</city>
        <state>Tochigi</state>
        <zip>329-0433</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <zip>123-0845</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/31033218/</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. J Diabetes Investig. 2019 Nov;10(6):1518-1526. doi: 10.1111/jdi.13066. Epub 2019 May 28.</citation>
    <PMID>31033218</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

